Gilman Law LLP Offering Free Lawsuit Evaluations to Actos Users Who Have Developed Bladder Cancer

Share Article

Potentially Thousands of People Who Developed Bladder Cancer Following Use of Actos May be Eligible to File an Actos Bladder Cancer Lawsuit Seeking Damages for Their Injuries

Gilman Law LLP Fighting For The Rights Of those Injured By Defective Drugs including those Diagnosed With Bladder Cancer While Taking Actos

Gilman Law LLP Fighting For The Rights Of those Injured By Defective Drugs including those Diagnosed With Bladder Cancer While Taking Actos

If You Took Actos And Have Developed Bladder Cancer Call Gilman Law Toll FREE at 1-877-428-7374 Now!

Recent research has indicated that people who use the type 2 diabetes medication, Actos, for a year or more face a higher risk of developing bladder cancer. In the U.S., the Food & Drug Administration (FDA) has issued two safety alerts since September 2010 regarding the link between Actos and bladder cancer. Gilman Law LLP is actively investigating potential lawsuits on behalf of the thousands of people who may have developed bladder cancer after using Actos. For more info on what you can do if you have been diagnosed with bladder cancer and took Actos, click here.

In its most recent alert, issued on (fda.gov/Drugs/DrugSafety/ucm259150.htm) June 15, 2011, the FDA warned that use of Actos for more than one year may be associated with an increased risk of bladder cancer. The June safety communication was a follow-up to one the agency issued in (fda.gov/Drugs/DrugSafety/ucm226214.htm) September 2010 after preliminary data from a Kaiser Permanente study demonstrated that the risk of bladder cancer rises with increasing dose and duration of Actos use. New bladder cancer warnings have since been added to the Actos label, and any other drugs containing pioglitazone, the active ingredient in Actos. For more info on Actos and bladder cancer click here.

Actos has also been the subject of similar safety warnings in Europe. In June, sales of Actos were suspended in France and Germany after a separate study commissioned by French regulators demonstrated an increased risk of bladder cancer associated with Actos in people who took it the longest and at the highest cumulative dose. In July, (takeda.com/press/article_42712.html) Takeda Pharmaceuticals, Inc. officially recalled Actos from the market in France.

Actos, known generically as pioglitazone hydrochloride, is the best-selling type 2 diabetes drug in the world. Pioglitazone is also found in Actoplus Met (pioglitazone/metformin), Actoplus Met XR (pioglitazone/metformin extended-release), and Duetact (pioglitazone/glimepiride).

Gilman Law LLP, a national law firm dedicated to protecting the rights of those injured by defective drugs and medical devices, is offering free, no obligation lawsuit consultations to the families of victims diagnosed with bladder cancer after using Actos, and is accepting Actos bladder cancer lawsuit clients on a contingency basis. More information regarding the association between Actos and bladder cancer, as well as the opportunity to arrange for your free lawsuit evaluation, is available at Gilmanlawllp.com. Free case evaluations may also be arranged by calling Toll Free at 1-877-428-7374.

Call Gilman Law Toll FREE at 1-877-428-7374 If You Took Actos And Have Developed Bladder Cancer! Call Gilman Law Toll FREE at 1-877-428-7374 Now!
 
Gilman Law LLP, a leading national law firm with offices in Florida and Massachusetts, has been recognized for delivering successful results to their clients across a broad range of claims stemming from consumer product injury, mass tort, and class action lawsuits. For over 32 years, the Gilman Law LLP team of highly experienced lawyers has earned renown for tireless work on behalf of their clients on many of today’s most challenging and important legal issues. Call Gilman Law Toll FREE at 1-877-428-7374 NOW!

Contact:
Gilman Law LLP
Call Gilman Law Toll FREE at 1-877-428-7374
Beachway Professional Center Tower
Suite 307
3301 Bonita Beach Road
Bonita Springs, FL 34134

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kenneth Gilman
Visit website